The FDA's push for lower-cost medicines looks good on paper, but the patent office under President Trump may be going in the ...
Dear reader, when we discuss the best-selling medications of all time, we’re exploring more than just products with massive ...
With immunology and inflammation blockbusters like AbbVie’s Skyrizi and Rinvoq reeling in nearly $7 billion combined in the ...
Drugmaker AbbVie sued the state in June because of Senate Bill 71, which forbade drug companies from limiting how many ...
Zacks.com on MSN
Amgen's Q3 Earnings in the Cards: Here's What to Expect
Amgen's Q3 results are on deck, with growth from newer drugs offset by biosimilar competition and pricing pressures.
Q3 2025 Sales Call October 30, 2025 4:00 AM EDTCompany ParticipantsCraig Marks - Head of Investor RelationsRichard Saynor ...
Oct 20 (Reuters) - AbbVie (ABBV.N), opens new tab said on Monday its newer arthritis drug Rinvoq showed superiority over the company's previous bestseller Humira in a head-to-head . AbbVie has been ...
Please provide your email address to receive an email when new articles are posted on . The FDA approved Yuflyma to treat hidradenitis suppurativa and uveitis in children. The expanded indications ...
FILE - Packaging for AbbVie's biologic drug, Humira, is photographed in Houston, July 18, 2014. (AP Photo/David J. Phillip, File) FILE - Packaging for AbbVie's biologic drug, Humira, is photographed ...
Federal regulators are trying to make it easier to develop cheaper alternatives to powerful drugs that many Americans depend on to treat autoimmune diseases or cancers. The Food and Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback